id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-320474-jyk7zphp	Bonaventura, Aldo	Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies	2020-07-03		.txt	text/plain	5082	242	38	Initial findings from patients with COVID-19 treated with a single intravenous dose of mavrilimumab, a monoclonal antibody binding GM-CSF receptor α, showed oxygenation improvement and shorter hospitalization. Data supporting the role of hyperinflammation in sepsisrelated acute respiratory distress syndrome (ARDS) are derived from a sub-group analysis of a phase 3 randomized controlled trial of IL-1 receptor antagonist (anakinra), which showed significant survival benefit in patients treated with anakinra compared to placebo (15) . APC, antigen presenting cell; DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. A randomized, double-blind, placebo-controlled phase II study tested the effects of low-dose hrGM-CSF (molgramostim, 3 µg/kg daily) for 5 days in patients in addition to the standard of care in critically ill patients with severe sepsis and respiratory dysfunction (65) .	./cache/cord-320474-jyk7zphp.txt	./txt/cord-320474-jyk7zphp.txt